Before considering care
A practical set of questions for prospective patients, families, and referring clinicians evaluating ibogaine treatment at Ambio.
Ask for specific answers, written documentation, and clear limits.
A careful starting point
These questions are not a substitute for individualized medical or legal advice. They are a way to make claims testable: ask what is done, who does it, when it happens, and what written record supports the answer.
Ibogaine is medically intensive and should be approached as investigational rather than as a proven cure. For broader context on the intervention and its uncertainty, begin with the core framework for evaluating ibogaine claims and safeguards, then compare a provider’s statements against the practical questions below.
01 / Status and eligibility
Legal status, clinical oversight, and eligibility standards are separate questions. Ask for the answer that applies where treatment would occur, not a general description of ibogaine.
Why it matters: Rules can differ by jurisdiction and may shape what oversight, emergency access, and accountability are available. What to look for: a precise explanation of the local legal setting and any relevant authorization or limitation, rather than a vague claim that the treatment is permitted.
Why it matters: Eligibility should not rest on a single broad intake conversation. What to look for: written exclusion criteria, a medication and health-history review, and a clear explanation of which clinician or medical professional makes the decision.
Why it matters: Screening claims are meaningful only when the tests and timing are clear. What to look for: an itemized pre-treatment plan that identifies tests, when they occur, who reviews them, and what happens if results are concerning.
Why it matters: Cardiac electrical activity is central to risk discussions around ibogaine. The FDA’s discussion of QT-related abnormal heart rhythms illustrates why a provider should be able to describe its specific thresholds and escalation process. What to look for: the actual cutoff, how it is measured, how medication interactions are assessed, and whether a result can delay or stop treatment.
02 / Dosing and observation
Questions about a dose are inseparable from questions about observation. A medication can have active metabolites, and the reference overview of ibogaine describes noribogaine as a metabolite associated with ibogaine. Ask Ambio how it accounts for this in its own process rather than assuming a general account describes an individual plan.
Acceptable answers should make a sequence visible: assessment, decision-making, observation, escalation, and discharge. The safety checklist for evaluating Ambio can help keep these operational questions separate from marketing claims.
03 / Emergency readiness
Risk management should be described in a sequence that a family member or referring clinician can understand.
Why it matters: A promise of care is not the same as a stated capability. What to look for: a direct account of equipment, staffing, training, availability by shift, and the circumstances that trigger an emergency response.
Why it matters: An actionable protocol clarifies who is responsible and what happens first. What to look for: a written or clearly described escalation sequence, including who evaluates the person, when emergency services are contacted, and how documentation is made.
Why it matters: Transfer time and coordination can matter in an emergency. What to look for: details about the receiving pathway, transport plan, records that travel with the patient, and whether the arrangement is documented rather than assumed.
Why it matters: Safety claims should be open to scrutiny. What to look for: definitions used for adverse events, who reviews them, whether follow-up is recorded, and what reporting obligations apply. The FDA MedWatch adverse-event reporting program is one example of why clear reporting pathways matter in regulated settings.
“Can you show me the policy, pathway, or record that supports that answer?”
That question is often more informative than asking for a guarantee. Documentation may include screening protocols, consent materials, medication-review procedures, monitoring records, transfer pathways, or a description of incident review. It should be understandable enough to support an informed conversation with an independent clinician or adviser.
04 / After the stay
Discharge is not the same as a continuing plan. Ask what follow-up is arranged, what circumstances call for urgent help, how information is shared with an existing clinician when appropriate, and how the plan accounts for relapse or a return of symptoms.
Useful answers identify responsibilities and timeframes without promising a particular result. They should distinguish what Ambio provides directly from what a person needs to arrange locally. For a clearer view of the standards this resource applies to claims and uncertainty, review the principles behind Still Threshold 24.
It can also be useful to ask what evidence the provider uses when discussing expected outcomes. The evidence brief on ibogaine at Ambio is designed to help separate an evidence question from a testimonial or a promotional statement.
Short answers
It would name the tests, timing, decision-maker, thresholds where applicable, medication review process, and what happens if a result changes the plan. General assurances that screening is “thorough” do not provide the same clarity.
It would describe the emergency sequence, on-site roles and capabilities, transport or emergency-service arrangements, the local receiving pathway, and how records are communicated. Ask whether the arrangement is documented.
No answer can remove uncertainty. A more credible discussion states what is known, what is not known, how risks are assessed, and what safeguards are actually in place for the individual situation.
Keep the questions specific
Bring this list to conversations with Ambio, your existing clinician, and the people supporting you. Ask for enough detail to understand what is claimed, what is documented, and what remains uncertain.